ImmunoPrecise Antibodies (IPA) Expected to Announce Earnings on Thursday

ImmunoPrecise Antibodies (NASDAQ:IPA) is expected to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunoPrecise Antibodies Stock Performance

Shares of IPA opened at $0.40 on Wednesday. The firm’s 50 day moving average price is $0.46 and its two-hundred day moving average price is $0.50. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. The firm has a market cap of $12.41 million, a P/E ratio of -0.51 and a beta of 0.09. ImmunoPrecise Antibodies has a twelve month low of $0.27 and a twelve month high of $1.71.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their price objective on shares of ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.